Edesa Biotech, Inc. announced a successful private placement led by Velan Capital, raising approximately $15 million to advance its CXCL10 antibody program through fiscal 2026. The offering included ...

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities ...

None of the securities issued have been registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent ...

Plus Therapeutics secured $3.7 million in private placement financing and $2 million from CPRIT for cancer therapy development. Plus Therapeutics, Inc., a clinical-stage pharmaceutical company focused ...

Private placement securities continue to offer insurers attractive opportunities to enhance portfolio income, according to a recent Conning report. Conning’s latest Viewpoint commentary, “Private ...

Rule 144A and Regulation D offer exemptions from federal securities registration requirements under the Securities Act of 1933. However, they apply to different situations, and overseas companies must ...

LYON, France--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA Adocia (Euronext Paris : ...

Stephen Twomey has published a new educational resource that explains how private placement funds operate under Rule 506(b) and what accredited investors should understand when evaluating these ...

Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir Imran At the ...

All monetary amounts are expressed in Canadian Dollars, unless otherwise indicated. TORONTO, Jan. 27, 2026 /PRNewswire/ - IsoEnergy Ltd. (NYSE American: ISOU) (TSX: ISO) (the "Company" or "IsoEnergy") ...